There were 238 press releases posted in the last 24 hours and 440,484 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image